Optimization of Parameters for Quantitative Analysis of 123 I-Ioflupane SPECT Images for Monitoring Progression of Parkinson Disease

J Nucl Med Technol. 2019 Mar;47(1):70-74. doi: 10.2967/jnmt.118.213181. Epub 2018 Aug 23.

Abstract

Quantitative assessment of dopamine transporter imaging can aid in diagnosing Parkinson disease (PD) and assessing disease progression in the context of therapeutic trials. Previously, the software program SBRquant was applied to 123I-ioflupane SPECT images acquired on healthy controls and subjects with PD. Earlier work on optimization of the parameters for differentiating between controls and subjects with dopaminergic deficits is extended here for maximizing change measurements associated with disease progression on longitudinally acquired scans. Methods: Serial 123I-ioflupane SPECT imaging for 51 subjects with PD (conducted approximately 1 y apart) were downloaded from the Parkinson Progression Markers Initiative database. The software program SBRquant calculates the striatal binding ratio (SBR) separately for the left and right caudates and putamen regions of interest (ROIs). Parameters were varied to evaluate the number of summed transverse slices and the positioning of the striatal ROIs for determining the signal-to-noise ratio associated with their annual rate of change in SBR. The parameters yielding the largest change in the lowest putamen's SBR from scan 1 to scan 2 were determined. Results: From scan 1 to scan 2 in the 51 subjects, the largest annual change was observed when the putamen ROI was placed 3 pixels away from the caudate and by summing 5 central striatal slices. This resulted in an 11.2% ± 4.3% annual decrease in the lowest putamen SBR for the group. Conclusion: Quantitative assessment of dopamine transporter imaging for assessing progression of PD requires specific, optimal parameters different from those for diagnostic accuracy.

Keywords: Parkinson disease; SPECT; brain; ioflupane; neurology; quantitative analysis.

MeSH terms

  • Case-Control Studies
  • Disease Progression*
  • Humans
  • Image Processing, Computer-Assisted / methods*
  • Nortropanes*
  • Parkinson Disease / diagnostic imaging*
  • Parkinson Disease / pathology
  • Software
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Nortropanes
  • ioflupane